Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.

Autor: Herting, Frank1, Friess, Thomas1, Umaña, Pablo2, Middleton, Steven3, Klein, Christian2 christian.klein.ck1@roche.com
Zdroj: Leukemia & Lymphoma. Jun2018, Vol. 59 Issue 6, p1482-1485. 4p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje